News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
83,331 Results
Type
Article (16696)
Company Profile (38)
Press Release (66577)
Multimedia
Podcasts (78)
Webinars (13)
Section
Business (25928)
Career Advice (907)
Deals (4621)
Drug Delivery (44)
Drug Development (8486)
Employer Resources (67)
FDA (1198)
Job Trends (2165)
News (39630)
Policy (2798)
Tag
2027 BioMidwest Elite (2)
2027 Biotech Bay Elite (1)
2027 Biotech Beach Elite (2)
2027 Genetown Elite (2)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (262)
Accelerated approval (9)
Adcomms (15)
Allergies (25)
Alliances (7241)
ALS (45)
Alzheimer's disease (243)
Antibody-drug conjugate (ADC) (138)
Approvals (1081)
Artificial intelligence (193)
Autoimmune disease (72)
Automation (9)
Bankruptcy (58)
Best Places to Work (891)
BIOSECURE Act (17)
Biosimilars (44)
Biotechnology (34)
Bladder cancer (35)
Brain cancer (20)
Breast cancer (78)
Cancer (994)
Cardiovascular disease (118)
Career advice (752)
Career pathing (29)
CAR-T (102)
CDC (6)
Cell therapy (272)
Cervical cancer (6)
Clinical research (6942)
Collaboration (618)
Company closure (6)
Compensation (25)
Complete response letters (41)
COVID-19 (442)
CRISPR (24)
C-suite (411)
Cystic fibrosis (26)
Data (834)
Denatured (18)
Depression (41)
Dermatology (20)
Diabetes (52)
Diagnostics (557)
Digital health (5)
Diversity (3)
Diversity, equity & inclusion (19)
Drug discovery (104)
Drug pricing (47)
Drug shortages (1)
Duchenne muscular dystrophy (79)
Earnings (5395)
Editorial (35)
Employer branding (8)
Employer resources (68)
Events (11433)
Executive appointments (353)
FDA (1581)
Friedreich's ataxia (3)
Frontotemporal dementia (8)
Funding (532)
Gene editing (72)
Generative AI (26)
Gene therapy (295)
GLP-1 (273)
Government (484)
Grass and pollen (1)
Guidances (29)
Healthcare (1187)
HIV (12)
Huntington's disease (32)
Idiopathic pulmonary fibrosis (1)
IgA nephropathy (25)
Immunology and inflammation (145)
Immuno-oncology (39)
Indications (17)
Infectious disease (522)
Inflammatory bowel disease (40)
Inflation Reduction Act (3)
Influenza (23)
Intellectual property (46)
Interviews (137)
IPO (1718)
IRA (11)
Job creations (1137)
Job search strategy (664)
JPM (46)
Kidney cancer (5)
Labor market (70)
Layoffs (247)
Leadership (31)
Legal (713)
Liver cancer (11)
Longevity (7)
Lung cancer (129)
Lymphoma (50)
Machine learning (19)
Management (22)
Manufacturing (304)
MASH (49)
Medical device (376)
Medtech (381)
Mergers & acquisitions (3078)
Metabolic disorders (323)
mRNA (89)
Multiple sclerosis (21)
NASH (7)
Neurodegenerative disease (128)
Neuropsychiatric disorders (39)
Neuroscience (586)
Neurotech (1)
NextGen: Class of 2026 (897)
Non-profit (271)
Now hiring (47)
Obesity (200)
Opinion (204)
Ovarian cancer (25)
Pain (25)
Pancreatic cancer (44)
Parkinson's disease (55)
Partnered (12)
Patents (82)
Patient recruitment (86)
Peanut (5)
People (11153)
Pharmaceutical (9)
Phase 1 (2631)
Phase 2 (3353)
Phase 3 (2113)
Pipeline (1178)
Policy (138)
Postmarket research (113)
Preclinical (980)
Press Release (53)
Prostate cancer (39)
Psychedelics (34)
Radiopharmaceuticals (71)
Rare diseases (346)
Real estate (1516)
Recruiting (38)
Regulatory (2493)
Reports (19)
Research institute (299)
Resumes & cover letters (152)
Rett syndrome (3)
RNA editing (14)
RSV (18)
Schizophrenia (30)
Series A (133)
Series B (76)
Service/supplier (3)
Sickle cell disease (18)
Special edition (20)
Spinal muscular atrophy (18)
Sponsored (14)
Startups (1258)
Stomach cancer (5)
Supply chain (25)
Tariffs (36)
The Weekly (59)
Vaccines (270)
Venture capital (102)
Weight loss (137)
Women's health (21)
Worklife (11)
Date
Today (3)
Last 7 days (101)
Last 30 days (438)
Last 365 days (4846)
2026 (2145)
2025 (4840)
2024 (5169)
2023 (5109)
2022 (6198)
2021 (6475)
2020 (5000)
2019 (4066)
2018 (3364)
2017 (4132)
2016 (3770)
2015 (4182)
2014 (5699)
2013 (6396)
2012 (2423)
2011 (2493)
2010 (2091)
Location
Africa (273)
Alabama (10)
Alaska (2)
Arizona (42)
Arkansas (2)
Asia (7475)
Australia (1181)
California (1431)
Canada (596)
China (390)
Colorado (46)
Connecticut (53)
Delaware (69)
Europe (18119)
Florida (236)
Georgia (26)
Hawaii (1)
Idaho (5)
Illinois (58)
India (18)
Indiana (48)
Iowa (4)
Japan (121)
Kansas (11)
Kentucky (6)
Louisiana (4)
Maryland (242)
Massachusetts (1267)
Michigan (25)
Minnesota (27)
Mississippi (1)
Missouri (21)
Montana (6)
Nebraska (4)
Nevada (23)
New Hampshire (3)
New Jersey (512)
New Mexico (6)
New York (401)
North Carolina (257)
North Dakota (1)
Northern California (641)
Ohio (52)
Oklahoma (8)
Oregon (6)
Pennsylvania (361)
Rhode Island (15)
South America (295)
South Carolina (4)
Southern California (607)
Tennessee (10)
Texas (212)
United States (5248)
Utah (39)
Virginia (23)
Washington D.C. (18)
Washington State (75)
West Virginia (1)
Wisconsin (22)
83,331 Results for "biotecher".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
IPO
Biotech’s IPO tide is finally turning, thanks in part to the recent M&A surge
After years of suffering from a bear market and more than 14 months of geopolitical turmoil shaking the macroenvironment, biotech appears to be moving on.
May 12, 2026
·
5 min read
·
Gabrielle Masson
Company closure
6 biotechs that called it quits in Q1
Six biotechs based in California, Massachusetts, Washington and Denmark had to halt drug development efforts this year. One of their CEOs is now in an interim chief executive role at another biotech.
April 30, 2026
·
6 min read
·
Angela Gabriel
IN PARTNERSHIP WITH
How To Shine As Biotech Comes Back From the Brink
Biotech has been pulling off some remarkable science of late, while M&A and IPOs return to bolster the sector. But that doesn’t mean the industry is back from the brink. BioSpace gathered three early-stage biotech CEOs and members of the NextGen Class of 2026 to talk about surviving and thriving in this rollercoaster market, all while bringing forward the next generation of medicines.
May 21, 2026
·
1 min read
·
Annalee Armstrong
FDA
Biotech leaders pitch Pazdur as next FDA chief
In a letter to President Donald Trump, a group of biotech executives recommended former cancer regulator Richard Pazdur to lead the agency after the departure of Marty Makary.
May 14, 2026
·
2 min read
·
Annalee Armstrong
Venture capital
Biotech has become a good news story. Let the sun shine
Doubling survival in pancreatic cancer, a long-fought rare disease approval, a massive IPO and ambitious biotech entrepreneurs have
BioSpace
Senior Editor Annalee Armstrong feeling upbeat about the biotech scene.
April 20, 2026
·
2 min read
·
Annalee Armstrong
Startup
Founders face pressure from all sides as biotech crawls toward recovery
In Salt Lake City, biotech founders new and seasoned reflect on ways to ride out the industry’s challenges, such as sending cold emails to investors and learning to address leadership weaknesses.
May 6, 2026
·
4 min read
·
Annalee Armstrong
Insights
Inside Germany’s biotech capital infrastructure and innovation engine
In this episode of Denatured, as part of our series on the European life sciences investment ecosystem, you’ll be hearing from Regina Hodits, managing director at Angelini Ventures and Sofia Ioannidou, VC partner at Andera Life Sciences. They explore Germany’s biotech and life sciences ecosystem, including the science, infrastructure and policy changes needed to help European companies scale globally while staying rooted in Europe.
May 21, 2026
·
1 min read
·
Jennifer C. Smith-Parker
Opinion
Biotech can’t continue to innovate under strain of Big Pharma market pressures
Biotech is increasingly financed, governed and regulated as though it were a mature pharmaceutical industry rather than a discovery system built around scientific uncertainty. Structural changes are needed to sustain the sector’s strategic innovation.
May 19, 2026
·
5 min read
·
Jeremy Levin
Opinion
To Survive the Downturn, Biotechs Must Return to Basics
In the current geopolitical and capital-market uncertainty, biotechs that have not mastered the basics are the ones struggling the most. Here’s how—and why—to get the details right.
April 8, 2026
·
5 min read
·
Driscoll R. Ugarte
Job Trends
Could biotech layoffs push life sciences talent to go global?
Amidst rising layoffs in key biotech hubs, global demand for specialized life sciences talent is driving a more borderless, distributed model of scientific work.
April 15, 2026
·
6 min read
·
Joanna Hart
1 of 8,334
Next